MINERVA NEUROSCIENCES INC

NERVNASDAQ

🏆 #3112 by market capEarnings Nov 3US Equity

$4.32▼ $0.28 (−6.49%)

🌅 Pre-market$4.32▲ 0.00%Regular close · extended-hours price shown

1h—

24h▼ 6.5%

7d▼ 0.7%

14d▲ 5.1%

30d▲ 0.7%

1y▲ 121.5%

🏦Market Cap

$201M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $4.29 – $4.38
52-Week Range: $1.76 – $12.46
Volume: $1.93B
Avg Volume: $2.13B
Shares Outstanding: 46.6M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $23M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-29.10
Dividend Yield: —

Why Investors Own NERV

✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$23M▲ +17.7% YoY

Gross Margin (TTM)

56.8%▲ +3.7% YoY

Operating Income (TTM)

$2M▲ +17.7% YoY

Free Cash Flow (TTM)

$3M▲ +17.7% YoY

About MINERVA NEUROSCIENCES INC

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

🦦